Literature DB >> 25438709

Pyrazoloquinazolines: Synthetic strategies and bioactivities.

Mansi Garg1, Monika Chauhan1, Pankaj Kumar Singh1, Jimi Marin Alex1, Raj Kumar2.   

Abstract

Numerous N-heterocycles are indisputably evidenced to exhibit myriad biological activities. In the recent past, attempts made to condense the various heterocycles have resulted in derivatives possessing better bioactivities. Among many such condensed heterocycles, pyrazoloquinazolines have managed to hold the attention of many researchers, owing to the broad spectrum of activities they portray. This review is the first of its kind to congregate the various pyrazoloquinazolines reported until now and categorizes these structurally isomeric classes into eleven different groups based on the fusion pattern of the ring such as [1,5-c], [5,1-b], [4,3-h], etc. Furthermore, this review is a concerted effort to highlight design, synthetic strategies as well as biological activities of each class of this condensed heterocycle. Structure-activity relationship studies and in silico approaches wherever reported have also been discussed. In addition, manuscript also offers scope for design, synthesis and generation of libraries of unreported classes of pyrazoloquinazolines for the biological evaluation.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biological activities; Docking; Pyrazoloquinazolines; QSAR; SAR; Synthetic strategies

Mesh:

Substances:

Year:  2014        PMID: 25438709     DOI: 10.1016/j.ejmech.2014.11.051

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment.

Authors:  Manvendra Kumar; Gaurav Joshi; Sahil Arora; Tashvinder Singh; Sajal Biswas; Nisha Sharma; Zahid Rafiq Bhat; Kulbhushan Tikoo; Sandeep Singh; Raj Kumar
Journal:  Molecules       Date:  2021-03-09       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.